University of California, Davis
Davis, California, 95616, United States
NCT Number: NCT03229863
This study is examining the relationship between infant nutrition, gut health, and development. The fecal microbiota changes and develops, in large part due to the food that infants eat. These changes are important for many aspects of development. This study is designed to examine how the fecal microbiota changes when exclusively breastfed infants are first introduced to solid food, and how changes of the fecal microbiota are related to other aspects of development.
This study is active but is not currently recruiting participants.
21 year–45 year
Female
Interventional
Not applicable
Davis, California, 95616, United States
The purpose of this study is to determine: 1) how the gut bacteria of exclusively breastfed infants changes in response to ingesting solid foods; 2) how infant cognition develops in response to ingesting solid foods; and 3) the relationship between infant gut bacteria and infant cognition during the first year of life.
This study is designed to determine how specific complex carbohydrates in commonly used first foods encourage the growth of different bacteria in the infant gut. The two foods used in this study are commercially-available sweet potato (Plum Organics) and pear (Earth's Best). These two foods have been chosen because they differ substantially from each other in their carbohydrate composition. For example, sweet potato is mostly made up of starch which is digestible and pear is made up of other types of sugars found in fruits and vegetables that are not digestible and may have "prebiotic" effects (food for good bacteria in the gut). Thus, the use of these two foods could provide a good contrast for comparing how gut bacteria respond to different carbohydrate compositions during complementary feeding.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Plum Organics, Just Sweet Potato
Earth's Best, First Pears
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The difference in the relative abundance of the infant fecal microbiome at the order level (top 22 taxonomic orders with abundance expressed as both on log10 scale and a percent of total bacteria) between baseline and post-complementary food intake for each intervention arm (sweet potato vs. pear).
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The difference in the infant fecal microbial diversity and microbial function between baseline and post-complementary food intake for each arm (sweet potato vs. pear)
Time frame: Baseline-days 180
Incidence of gastrointestinal symptoms (discomfort passing bowel movements, vomiting, constipation, colic or irritability), illnesses, health care visits for sickness, high fevers, antibiotic and medication use.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The relationship between the relative abundance of the infant fecal microbiome and function, and food glycan composition.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The relationship between the relative abundance of the infant fecal microbiome, microbial diversity and function, and infant cognition measured at 6, 8 and 12 months of age
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The relationship between the relative abundance of the infant fecal microbiome, microbial diversity and function, and infant sleep, activity and vocalizations measured throughout the study period.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The relationship between maternal secretor status (via measurement of human milk oligosaccharides in breast milk) and the relative abundance of the infant fecal microbiome, microbial diversity and function before, during and after introduction of complementary foods.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The relationship between infant secretor status (via measurement of oligosaccharides in saliva) the relative abundance of the infant fecal microbiome, microbial diversity and function before, during and after introduction of complementary foods.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The relationship between maternal and infant fecal microbiome.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
The change in infant fecal human milk oligosaccharide concentrations before, during and after introduction of complementary foods.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
Determine the relationship between infant weight and the relative abundance of the infant fecal microbiome, microbial diversity and function before, during and after introduction of complementary foods
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
Determine the relationship between human milk metabolomics (metabolites, fatty acids, proteins) and the infant fecal microbiome.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
Determine the relationship between fecal metabolites (metabolites, fatty acids, proteins) and fecal microbiome.
Time frame: Change from baseline, days 14, 19, 25, 29, 60, 90, 120, 150, 180
Change in GI function as a means to monitor tolerability before, during and after introduction of complementary foods (through the measurement of fecal inflammatory mediators, GI barrier function markers and fecal LPS).
Time frame: Change from baseline to day 29
Evaluate the glycosidic linkages in interventional foods and the infant fecal microbiome.
University of California, Davis
Other
The Infant MiND Study: An Examination of Infants' Microbiome, Nutrition, and Development Study.
Acronym: IMiND
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04992104
Behavior, Breast Feeding
Toronto, Canada
View Trial DetailsNCT05815433
Behavior, Breast Feeding
Calgary, Alberta, Canada
View Trial DetailsNCT05934422
Allergy, Atopic Dermatitis
Auckland, New Zealand
View Trial DetailsNCT05923333
Acquired Immunodeficiency Syndrome, Blood-Borne Infections
Cape Town, South Africa
View Trial Details